Literature DB >> 15154823

Risk management : a European regulatory perspective.

Jane N S Moseley1.   

Abstract

Risk management for European regulators means the detection and assessment of risks, the development and selection of measures to reduce risk, and monitoring of the effectiveness of risk control; all aspects of pharmacovigilance intended to minimise risk to European Union citizens associated with use of medicinal substances. This incorporates earlier and better planning of pharmacovigilance through formal product risk-management plans, better use of information tools to protect public health and routine audit of effectiveness of regulatory action.

Mesh:

Year:  2004        PMID: 15154823     DOI: 10.2165/00002018-200427080-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  1 in total

1.  A model for the future conduct of pharmacovigilance.

Authors:  Patrick C Waller; Stephen J W Evans
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Jan-Feb       Impact factor: 2.890

  1 in total
  2 in total

Review 1.  Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Authors:  Craig G Hartford; Kasia S Petchel; Hani Mickail; Susana Perez-Gutthann; Mary McHale; John M Grana; Paula Marquez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Risk undermined in the bilateral pharmaceutical regulatory system in Taiwan.

Authors:  Hui-Po Wang; Chun-Li Wang
Journal:  J Food Drug Anal       Date:  2018-01-17       Impact factor: 6.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.